Name
GS3-06: Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial.
Date & Time
Friday, December 13, 2024
Speakers
Virtual Session Link
Total Minutes
06:27
OnDemand Video URL